Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Disregulated Wnt/β-catenin signaling has been linked to various human diseases, including cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in cancers. LRP5 and LRP6 are closely related membrane coreceptors for Wnt proteins. Using a phage-display library, we identified anti-LRP6 antibodies that either inhibit or enhance Wnt signaling. Two classes of LRP6 antagonistic antibodies were discovered: one class specifically inhibits Wnt proteins represented by Wnt1, whereas the second class specifically inhibits Wnt proteins represented by Wnt3a. Epitope-mapping experiments indicated that Wnt1 class-specific antibodies bind to the first propeller and Wnt3a class-specific antibodies bind to the third propeller of LRP6, suggesting that Wnt1- and Wnt3a-class proteins interact with distinct LRP6 propeller domains. This conclusion is further supported by the structural functional analysis of LRP5/6 and the finding that the Wnt antagonist Sclerostin interacts with the first propeller of LRP5/6 and preferentially inhibits the Wnt1-class proteins. We also show that Wnt1 or Wnt3a class-specific anti-LRP6 antibodies specifically block growth of MMTV-Wnt1 or MMTV-Wnt3 xenografts in vivo. Therapeutic application of these antibodies could be limited without knowing the type of Wnt proteins expressed in cancers. This is further complicated by our finding that bivalent LRP6 antibodies sensitize cells to the nonblocked class of Wnt proteins. The generation of a biparatopic LRP6 antibody blocks both Wnt1- and Wnt3a-mediated signaling without showing agonistic activity. Our studies provide insights into Wnt-induced LRP5/6 activation and show the potential utility of LRP6 antibodies in Wnt-driven cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 1×
“In addition, Wnt signaling plays a critical role in the homeostatic regulation of tissue stem cells and hence, is implicated in the maintenance of cancer stem cells (17, 18).”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 3×
“How SOST deficiency increases bone density is not well-understood, although SOST proteins show reduced binding to LRP5 HBM mutants (25, 27).”
BackgroundLittle, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · cited 1×
“Wnt signaling promotes bone formation by increasing the growth and differentiation of osteoblasts (19), and in humans, gain-of-function mutations of LRP5 (10, 20) and lossof-function mutations of Wnt antagonist SOST (21, 22) lead to high bone-mass diseases.”
BackgroundBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011 · cited 1×
“Wnt signaling promotes bone formation by increasing the growth and differentiation of osteoblasts (19), and in humans, gain-of-function mutations of LRP5 (10, 20) and lossof-function mutations of Wnt antagonist SOST (21, 22) lead to high bone-mass diseases.”
BackgroundSOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Structure of the LDL Receptor Extracellular Domain at Endosomal pH
Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., & Deisenhofer, J. (2002) · Science · doi:10.1126/science.1078124 · Cited by 482 · cited 2×
“In LDLR, the intramolecular interaction between the LDLR domain and the β-propeller domain controls LDL binding and release from LDLR (34).”
BackgroundWg/Wnt Signal Can Be Transmitted through Arrow/LRP5,6 and Axin Independently of Zw3/Gsk3β Activity
Tolwinski, N. S., Wehrli, M., Rives, A., Erdeniz, N., DiNardo, S., & Wieschaus, E. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00063-7 · Cited by 286
Mesd Encodes an LRP5/6 Chaperone Essential for Specification of Mouse Embryonic Polarity
Hsieh, J.-C., Lee, L., Zhang, L., Wefer, S., Brown, K., DeRossi, C., Wines, M. E., Rosenquist, T., & Holdener, B. C. (2003) · Cell · doi:10.1016/s0092-8674(03)00045-x · Cited by 237
Cited by
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
Self-citationWnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Basing on these facts, LRP6 neutralizing antibodies were demonstrated to repress tumorigenesis.(116) It is of note that contrarily targeting Lrp5/6 may be not eligible for managing metastasis of breast cancer.”
BackgroundFrizzled and LRP5/6 Receptors for Wnt/ -Catenin Signaling
MacDonald, B. T., & He, X. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007880 · Cited by 612
The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators
Rim, E. Y., Clevers, H., & Nusse, R. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-040320-103615 · Cited by 483
Metadata
- Authors
- Ettenberg, S. A., Charlat, O., Daley, M. P., Liu, S., Vincent, K. J., Stuart, D. D., Schuller, A. G., Yuan, J., Ospina, B., Green, J., Yu, Q., Walsh, R., Li, S., Schmitz, R., Heine, H., Bilic, S., Ostrom, L., Mosher, R., Hartlepp, K. F., Zhu, Z., Fawell, S., Yao, Y.-M., Stover, D., Finan, P. M., Porter, J. A., Sellers, W. R., Klagge, I. M., & Cong, F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-08-16
- Volume
- 107
- Issue
- 35
- Pages
- 15473-15478
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2084517025
- Cited by
- 150
- References
- 11
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.